Clinical trial

Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

NCT02702401

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Pembrolizumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Best Supportive Care Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-05-26

PhasePHASE3

Conditions

Hepatocellular Carcinomaverified · MONDO: hepatocellular carcinoma

Interventions

PembrolizumabBIOLOGICAL

PlaceboDRUG

Best Supportive CareOTHER

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02702401 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.